Adrenomedullin is a neuropeptide known for its cardiovascular activities and anti-inflammatory effects. Here, we investigated the effect of adrenomedullin in a model of experimental autoimmune encephalomyelitis (EAE) that mirrors chronic progressive multiple sclerosis. A short-term systemic treatment with adrenomedullin reduced clinical severity and incidence of EAE, the appearance of inflammatory infiltrates in spinal cord and the subsequent demyelination and axonal damage. This effect was exerted at multiple levels affecting both early and late events of the disease. Adrenomedullin decreased the presence/activation of encephalitogenic Th1 and Th17 cells and down-regulated several inflammatory mediators in peripheral lymphoid organs and central nervous system. Noteworthy, adrenomedullin inhibited the production by encephalitogenic cells of osteopontin and of Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), two critical cytokines in the development of EAE. At the same time, adrenomedullin increased the number of IL-10-producing regulatory T cells with suppressive effects on the progression of EAE. Furthermore, adrenomedullin generated dendritic cells with a semi-mature phenotype that impaired encephalitogenic responses in vitro and in vivo. Finally, adrenomedullin regulated glial activity and favored an active program of neuroprotection/regeneration. Therefore, the use of adrenomedullin emerges as a novel multimodal therapeutic approach to treat chronic progressive multiple sclerosis.
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Introduction
Multiple sclerosis (MS) is a disabling demyelinating disease of the central nervous system (CNS) affecting more frequently young people. Although the mechanisms of disease pathogenesis remain unclear, MS is considered as an archetypal neuroinflammatory and autoimmune disease in which Th1 and Th17 CD4 cells reactive to components of the myelin sheath infiltrate the CNS parenchyma, release proinflammatory cytokines and chemokines, and further promote inflammatory cell infiltration and activation (Goverman, 2009; Steinman, 1996) . The production of inflammatory mediators such as cytokines and free radicals by infiltrating immune cells and resident glial cells plays a critical destructive role in the process of demyelination and contributes to oligodendrocyte loss and axonal degeneration. Moreover, evidence indicates that a deregulation in the mechanisms involved in the maintenance of immune tolerance, especially those affecting regulatory T (Treg) cells, critically contributes to the establishment and progression of the autoimmune response (Viglietta et al., 2004) . Although available therapies based on immunosuppressive agents reduce the relapse rate or delay disease onset, they do not suppress progressive clinical disability. Therefore, we need novel multistep therapeutic approaches that prevent the inflammatory and autoimmune components of the disease, restore immune tolerance and promote and/or allow mechanisms of neuroprotection and neuroregeneration.
Adrenomedullin is a 52-aa neuropeptide belonging to the family of calcitonin-gene related peptide (CGRP) that was initially discovered through its vasodilatory activity and cardiovascular protective actions (Kitamura et al., 1993) . Recent evidence indicates that adrenomedullin is a major regulator of the immune response. Besides its presence in the CNS and cardiovascular system (Hinson et al., 2000) , adrenomedullin and its receptors are expressed by macrophages, monocytes, T cells and dendritic cells (DCs), mainly in response to inflammatory and immune stimulation (Elsasser and Kahl, 2002; Ishimitsu et al., 1998; Kubo et al., 1998a,b; Rullé et al., 2012; Yang et al., 2001 ). Moreover, adrenomedullin shows potent
